What the FDA labels say about taking them together
Atropine and remifentanil
Remifentanil's FDA label of December 15, 2025 names atropine in its warnings and precautions section; the atropine labels PlainMeds reads (4) do not name remifentanil.
Check it at the source: the atropine FDA label on DailyMed (effective May 18, 2026, Hospira, Inc.); the remifentanil FDA label on DailyMed (effective December 15, 2025, Mylan Institutional LLC).
What does the atropine label say about remifentanil?
Atropine's label (effective May 18, 2026) and its 3 other brand-application labels do not name remifentanil in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Atropine Sulfate), Hospira, Inc., effective May 18, 2026 (SPL set ad8916e7-206e-409e-2582-30d072845dd4), via openFDA; the full label on DailyMed
What does the remifentanil label say about atropine?
Remifentanil label, warnings and precautionsBradycardia has been reported with ULTIVA and is responsive to ephedrine or anticholinergic drugs, such as atropine and glycopyrrolate.
Source: FDA drug label (Ultiva), Mylan Institutional LLC, effective December 15, 2025 (SPL set 4dbcb8f9-1987-4b66-bd2f-d251fda0be10), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Atropine | Remifentanil | |
|---|---|---|
| Labeled for | n/a | n/a |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $7.74 per mL 1% eye drops | n/a |
| Shortage now | In shortage | In shortage |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once